IRIS - Res&Arch Institutional Research Information System - Research & Archive

LIBERATI, Anna Marina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.454
EU - Europa 6.962
AS - Asia 1.534
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 18
SA - Sud America 7
AF - Africa 3
Totale 16.004
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.426
IE - Irlanda 1.693
UA - Ucraina 1.374
IT - Italia 1.077
SE - Svezia 1.018
VN - Vietnam 670
HK - Hong Kong 584
FI - Finlandia 498
DE - Germania 433
RU - Federazione Russa 405
CN - Cina 131
GB - Regno Unito 127
FR - Francia 96
CH - Svizzera 66
AT - Austria 53
TR - Turchia 50
UZ - Uzbekistan 36
NL - Olanda 29
AU - Australia 26
SG - Singapore 24
RO - Romania 19
EU - Europa 18
GR - Grecia 18
CA - Canada 17
PL - Polonia 17
LB - Libano 16
CZ - Repubblica Ceca 15
BE - Belgio 13
MX - Messico 10
KR - Corea 9
IN - India 5
BR - Brasile 4
BG - Bulgaria 3
ID - Indonesia 3
IL - Israele 3
MT - Malta 2
PE - Perù 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
CL - Cile 1
CR - Costa Rica 1
EG - Egitto 1
ES - Italia 1
IR - Iran 1
JP - Giappone 1
MA - Marocco 1
TN - Tunisia 1
TW - Taiwan 1
VA - Santa Sede (Città del Vaticano) 1
Totale 16.004
Salva come PNG Salva come JPEG
Città #
Dublin 1.693
Chandler 1.371
San Mateo 1.079
Dong Ket 667
Hong Kong 583
Altamura 491
Medford 479
Princeton 478
Wilmington 406
Lawrence 371
Andover 351
Jacksonville 312
Perugia 252
Ann Arbor 210
Des Moines 144
Saint Petersburg 136
Boardman 100
Norwalk 93
Beijing 89
Falls Church 69
Ashburn 66
San Paolo di Civitate 64
Izmir 47
Woodbridge 47
Helsinki 44
Houston 39
Los Angeles 35
Moscow 33
Redwood City 20
Shanghai 19
Vienna 19
Dearborn 18
Den Haag 18
Frankfurt Am Main 17
Redmond 17
Port Pirie 16
New York 15
Brussels 13
Bucharest 11
Singapore 11
Piediluco 10
Auburn Hills 9
Tappahannock 9
Lausanne 8
Perth 8
Rome 8
Torino 7
Bologna 6
Terni 6
Timisoara 6
Assisi 5
Cambridge 5
Chicago 5
Florence 5
Kiev 5
Ottawa 5
Ancona 4
Giacciano con Baruchella 4
Hanover 4
Minneapolis 4
Modena 4
Napoli 4
Pozzuoli 4
Atlanta 3
Bari 3
Ceppaloni 3
Chalco 3
Chengdu 3
Dallas 3
Foligno 3
Fremont 3
Hanoi 3
Merate 3
Milan 3
Nürnberg 3
Palermo 3
Philadelphia 3
Seodaemun-gu 3
Simi Valley 3
Surabaya 3
Toronto 3
Winnipeg 3
Bordeaux 2
Bratislava 2
Buffalo 2
Callao 2
Corciano 2
Costa Mesa 2
Graz 2
Guangzhou 2
Iesi 2
Kocaeli 2
Lisbon 2
London 2
Ludwigshafen 2
Luft 2
Marsaxlokk 2
Messina 2
Mexico City 2
Mississauga 2
Totale 10.171
Salva come PNG Salva come JPEG
Nome #
WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) 122
Integration of Traditional and Western Medicine in Vietnamese Populations: A Review of Health Perceptions and Therapies 120
[Metastatic gastric cancer successfully treated with surgery and chemotherapy. Case report]. 86
Artocarpus tonkinensis protects mice against collagen-induced arthritis and decreases Th17 cell function 86
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. 80
Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome? 78
Cell membrane markers and phytohemagglutinin reactivity of circulating lymphocytes from chronic myelocytic leukemia patients. 78
L'interferone alfa nella leucemia mieloide cronica 77
Prognosi e terapia del mieloma multiplo. 77
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 74
Evaluation of response to therapy with 67Ga scintigraphy, CT scan and magnetic resonance in malignant lymphomas. 74
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. 73
Antibodies binding granulocyte-macrophage colony stimulating factor produced by cord blood-derived B cell lines immortalized by Epstein-Barr virus in vitro. 72
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients 71
Anti-cancer activity of compounds isolated from Bursera microphylla 71
67Ga scan detects residual active disease and it is predictive of disease-free survival in malignant lymphoma patients. 70
SUMO proteins: Guardians of immune system 70
All-trans-retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 70
Indicazione all’autotrapianto in prima linea nel linfoma non-Hodgkin’s aggressivo. 69
67Ga scan detects residual active disease and it is predictive of disease-free survival in malignant lymphoma patients 69
R-CHOP vs R-miniCEOP for the initial treatment of elderly “fit“ patients with diffuse large B-cell lymphoma. Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi (IIL) 67
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. 67
Isolation and identification of bioactive molecules from resins used in traditional medicine: Commiphora erythraea and Bursera microphylla 66
Anti-rheumatoid arthritis activity of decoction from the leaves of the tree Artocarpus tonkinensis used in Vietnamese traditional medicine 66
Complex translocations of the Ph chromosome and Ph-negative CML arise from similar mechanisms as evidenced by FISH analysis. 66
The role of autotransplantation in chronic lymphocytic leukemia and results from the italian group. 65
Natural-killer-stimulatory effect of combined low-dose interleukin-2 and interferon beta in hairy-cell leukemia patients. 65
Fattori prognostici nel carcinoma colon-retto. 65
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. 64
Effectiveness and Safety of Combined Cytoreductive Therapy In 56 Patients With Essential Thrombocythaemia: Report of the Registro Italiano Trombocitemie (rit) 64
Myelomonocytic-associated antigens in a case of genotypically, phenotypically and functionally B-cell lymphoma. 63
In vitro synergistic activity of PDN-IFN alpha and NM + IFN alpha combinations on fresh bone-marrow samples from multiple myeloma patients. 63
Anagrelide in essential thrombocythemia: a retrospective analysis of 220 patients 63
67Ga-scan detects residual active disease and it is predictive of disease-free survival in classical Hodgkin's disease patients 62
Conventional induction treatments do not influence overall survival in multiple myeloma. 62
GM-CSF: clinical trials in non-Hodgkin's lymphoma patients with chemotherapy induced leucopenia. 62
Lenalidomide and its role in the management of multiple myeloma. 62
Monitoring treatment and survival in chronic myeloid leukemia. 61
Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. 61
Staging of chronic myeloid leukaemia. 61
Rare immunological presentation in B-cell chronic lymphocytic leukaemia. 61
Pharmacologic and immunologic effects of human leukocyte interferons in patients with neoplasia: an interim report. 61
Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer. 61
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. 60
Pre-autologous stem cell transplantation (ASCT) treatment with rituximab does not impair stem cell harvest and engraftment in untreated patients with diffuse large B-cell lymphoma (B-DLCL) at poor prognosis 59
Effect of adding Rituximab to intensified and high dose chemotherapy(HDC)with ASCT as first line treatment in stage III-IV at intermediate-high (IH) and high risk (HR) diffuse large B-cell lymphoma 59
Treatment of Ph-positive Chronic Myeloid Leukemia with alpha-Interferon (Roferon-A). The Italian Cooperative Study Group experience. 58
Pharmacological modulation of caspase-8 in thymus-related medical conditions. 58
Anti-cancer activity of compounds isolated from Bursera microphylla. 58
Interferon Alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia. A study of 82 patients treated with intermittent administration. 57
67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma 57
Long term outcome of Ph plus CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 57
Melphalan 200 mg/m2 versus Melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multi-center phase III study. 56
Phase I-II trial on natural beta interferon in chemoresistant and relapsing multiple myeloma. 55
Allogeneic hematopoietic stem cell transpalntation in children and adolescent with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. 55
A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): An interim analysis. 55
L’approccio terapeutico nell’anziano con mielodisplasia. 55
A 4-day chemosensitivity assay in vitro reliably predicts clinical response of patients with acute leukemia 54
Has 67Ga-scan a role in the evaluation of lymphoma response to conventional or high dose chemotherapy? 53
Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia(RIT) 53
Bcl-xL overexpression decreases GILZ levels and inhibits glucocorticoid-induced activation of caspase-8 and caspase-3 in mouse thymocytes 53
A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD) 52
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. 52
Citotossicità spontanea in pazienti con B-LLC. 52
A Prospective Randomized Trial of Bortezomib-melphalan-prednisone-thalidomide Followed By Continuous Bortezomib-thalidomide For Initial Therapy of Multiple Myeloma: Effect of Age and Co-morbidities 52
Ph '-positive (Ph '+) chronic myeloid leukemia (CML) presenting as Ph ' plus T-lymphoblastic lymphoma (LL) resistant to high-dose chemotherapy and Gleevec. 51
Evaluation of response therapy with 67Ga scintigraphy, CT scan and magnetic resonance in malignant lymphomas. 51
Interferon-alpha-2b as therapy for untreated and pretreated patients with Ph' positive chronic myeloid leukemia 51
Complete response correlates with long-term progression-free and overall survivals in elderly myeloma treated with novel agents: analysis of 1175 patients 51
High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: A preliminary experience. 51
Addition of rituximabto dose-denseand high dose chemotherapy with autologous transplantation in untreated poor-prognosis diffuse large B-cell lymphoma: Results of phase II trial 51
Chronic Myeloid Leukemia In Blast Crisis Treated With Imatinib 600 Mg: Outcome of the Patients Alive After A 6-year Follow-up 51
A prospective randomized controlled trial of oral melphalan, prednisone, thalidomide versus oral melphalan, prednisone in elderly newly diagnosed myeloma patients 51
Lenalidomide in the treatment of lymphoproliferative disorders and multiple myeloma. 51
Differences among young adults, adults and elderly chronic myeloid leukemia patients 51
Maesopsin 4-O-D-glucoside, a natural compound isolated from the leaves of Artocarpus tonkinensis, inhibits proliferation and up-regulates HMOX1, SRXN! and BCAS3 in acute myeloid leukemia 51
67Ga-scan usefulness in predicting the clinical outcome and the long-term effects of chemotherapy in lymphoma patients 50
5-Fluorouracil, vincristine and hydroxyurea combination chemotherapy in metastatic colorectal cancer. 50
A brief course of chemo-immunotherapy FND plus rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis. 50
Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with Rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: An interim analysis. 50
Evaluating survival after allogeneic bone marrow transplant for chronic myeloid leukaemia in chronic phase: a comparison of transplant versus no transplant in cohort of 258 patients first seen in Italy between 1984 and 1986. 50
Electrophysiological and neuropsychological functions in patients treated with interferon-beta. 49
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study. 49
The value of molecular response in chronic myeloid leukaemia: the present and the future. 49
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. 48
L'interferone nel trattamento della leucemia mieloide cronica Philadelphia positiva. 48
A case of acute myeloid leukemia with deletion of chromosome 7 following PBSC transplantation. 48
The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases 48
A continous recurrent course in a case of nodular-sclerosis (NS) classical Hodgkin's lymphoma (cHL) associated with Castleman's disease (CD) 48
Esordio apparentemente cutaneo di linfoma maligno a linfociti B e cellule nulle. 48
Could thymomectomy be a reasonable option for non-myasthenic thymoma patients? 48
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma 48
Immunologic profile in patients with Hodgkin's disease in complete remission. 47
VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study 46
Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients:A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL) 46
Rapid and sustained response of an intra- and extracranial large cell lymphoma mass to liposomal intrathecal Ara-C and R-MegaCEOP systemic chemotherapy. 46
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 46
Bendamustine (b) In Combination With Rituximab (r) For Patients With Relapsed/resistant Chronic Lymphocytic Leukemia (cll): An Italian Multicentre Retrospective Study 46
A prospective, randomized, phase III study of melphalan 200 mg/m(2) (Mel200) versus melphalan 100 mg/m(2) (Mel100) in newly diagnosed myeloma patients 46
Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data 46
Totale 5.976
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.292
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.292
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201986 0 0 0 0 0 0 0 0 0 0 70 16
2019/20201.046 23 168 129 13 74 11 115 4 367 49 22 71
2020/20213.377 13 317 116 310 1.037 202 99 24 242 108 169 740
2021/20223.652 63 696 57 123 125 55 63 1.377 39 67 385 602
2022/20235.594 512 1.044 31 395 402 609 7 253 2.147 6 151 37
2023/20241.254 137 213 107 32 20 15 555 26 80 67 2 0
Totale 17.270